Charles River Laboratories’ second quarter results were shaped by recovering biopharmaceutical demand and the impact of portfolio streamlining. Management highlighted that the rebound was most evident in the Discovery and Safety Assessment (DSA) segment, where net book-to-bill reached a four-year high and organic revenue growth turned positive for the first time since 2023. CEO Birgit Girshick pointed to an uptick in proposal activity and improved funding for small and midsize biotech clients as critical factors that helped stabilize revenues, even as North American academic and government spending remained subdued. The divestiture of non-core businesses provided an immediate operating margin benefit, with the Manufacturing segment seeing notable improvement.
Is now the time to buy CRL? Find out in our full research report (it’s free for active Edge members).
Charles River Laboratories (CRL) Q2 CY2026 Highlights:
- Revenue: $1.00 billion vs analyst estimates of $979.9 million (2.7% year-on-year decline, 2.5% beat)
- Adjusted EPS: $3.02 vs analyst estimates of $2.74 (10.3% beat)
- Management raised its full-year Adjusted EPS guidance to $11.30 at the midpoint, a 2.3% increase
- Operating Margin: 11.9%, up from 9.7% in the same quarter last year
- Organic Revenue was flat year on year (beat)
- Market Capitalization: $13.46 billion
While we enjoy listening to the management’s commentary, our favorite part of earnings calls is the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions From Charles River Laboratories’s Q2 Earnings Call
-
Kallum Titchmarsh (Morgan Stanley) asked about AI’s role in preclinical pipelines; CEO Birgit Girshick said AI-driven drug discovery should eventually increase demand for validation and safety studies, but material impact will take time.
-
Ann Hynes (Mizuho) questioned the risk from Chinese CROs; Girshick explained that while competition is rising, most regulated safety work remains in Western labs, and Charles River is prepared to differentiate through service and supply chain.
-
David Windley (Jefferies) asked about NHP supply and margin cadence; Girshick and Coleman clarified that the main cost benefits from Cambodian NHPs would be recognized in Q4, not Q3, due to quarantine and study timelines.
-
Charles Rhyee (TD Cowen) inquired if Q4 should be considered the new baseline for margins; Coleman advised against annualizing Q4 results, noting exceptional factors and ongoing portfolio transitions.
-
Elizabeth Anderson (Evercore ISI) questioned service mix in bookings; Girshick said there is a shift to more pre-IND (early-stage) work, which supports later-stage growth and improves long-term pipeline visibility.
Catalysts in Upcoming Quarters
In the coming quarters, our team will monitor (1) the pace at which DSA bookings convert to revenue, (2) realization of margin benefits from integrated NHP supply and Manufacturing segment improvements, and (3) progress on digital pathology and bioanalysis capacity expansions. We will also track whether the biopharma funding environment continues to bolster demand from smaller biotech clients, as well as signs of recovery in academic and government research spending.
Charles River Laboratories currently trades at $281.81, up from $234.12 just before the earnings. In the wake of this quarter, is it a buy or sell? See for yourself in our full research report (it’s free).
High-Quality Stocks for All Market Conditions
ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.
Find out which 5 stocks it’s flagging this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+214% between June 2020 and June 2025). Find your next big winner with StockStory today.
